glp-1 drugs thyroid cancer agonist like Ozempic do not increase risk GLP-1RA and thyroid cancer: New

No blinding was used in the initial mouse study, though the CROs conducting the second mouse study and the NHP study were blinded to the antibodies we supplied

Methodology Primary Research: Interviews with endocrinologists, clinical pharmacologists, and pharmaceutical market experts

If needle phobia is a particular issue, discussion of options that have the needle hidden and/or have a pre-attached needle, which require minimal handling by the patient, could be considered

Question: How have manufacturers of brand-name glucagon-like peptide-1 (GLP-1) receptor agonists used the patent and regulatory system to extend periods of market exclusivity

The researchers also couldn't account for some factors, such as socioeconomic status or lifestyle choices, that could affect the results